Table 1.
Baseline characteristics in MINOCA patients based on tertiles of fT3/fT4 ratio.
| Variable | Tertile1 (n=387) | Tertile2 (n=386) | Tertile3 (n=389) | p value |
|---|---|---|---|---|
| Male, n(%) | 300 (77.5%) | 291 (75.3%) | 265 (68.1%) | <0.001 |
| Age, years | 54.0±12.3 | 55.1±11.6 | 57.8±11.1 | <0.001 |
| BMI, kg/m2 | 25.2±3.5 | 25.4±3.8 | 25.8±3.9 | 0.252 |
| STEMI, n(%) | 128 (33.0%) | 155 (40.1%) | 173 (44.4%) | 0.022 |
| Past history | ||||
| Hypertension | 195 (50.3%) | 204 (52.8%) | 220 (56.5%) | 0.035 |
| Diabetes | 51 (13.1%) | 57 (14.7%) | 75 (19.2%) | 0.043 |
| Dyslipidemia | 231 (59.6%) | 225 (58.2%) | 217 (55.7%) | 0.172 |
| Previous MI | 18 (4.6%) | 20 (5.1%) | 20 (5.1%) | 0.931 |
| Killip class≥2, n(%) | 21 (5.4%) | 29 (7.5%) | 36 (9.2%) | 0.036 |
| LVEF, % | 61.2±6.0 | 60.9±6.0 | 59.4±7.5 | <0.001 |
| TIMI risk score | 3.2±1.1 | 3.4±1.2 | 3.7±1.5 | 0.002 |
| Laboratory test | ||||
| fT3, pg/mL | 3.03±0.36 | 2.87±0.31 | 2.56±0.39 | <0.001 |
| fT4, ng/dL | 1.04±0.13 | 1.17±0.13 | 1.28±0.19 | <0.001 |
| fT3/fT4 ratio | 2.93±0.27 | 2.46±0.10 | 2.01±0.21 | <0.001 |
| TSH, μIU/mL | 2.13±1.51 | 2.14±1.59 | 2.08±1.33 | 0.162 |
| FBG, mmol/L | 5.53±1.55 | 5.60±1.51 | 5.95±1.92 | 0.001 |
| LDL-C, mmol/L | 2.28±0.78 | 2.30±0.73 | 2.29±0.76 | 0.901 |
| Creatinine, μmol/L | 78.9±14.5 | 79.9±15.2 | 81.4±18.7 | 0.566 |
| hs-CRP, mg/L | 1.98 (0.95, 4.40) | 2.09 (1.07, 5.17) | 2.86 (1.17, 8.40) | <0.001 |
| NT-proBNP, pg/mL | 302 (107, 653) | 351 (118, 695) | 403 (121, 786) | 0.023 |
| TnI, ng/mL | 1.31 (0.32, 3.73) | 1.52 (0.41, 4.85) | 1.76 (0.72, 5.13) | 0.011 |
| In-hospital medication | ||||
| DAPT | 353 (91.2%) | 364 (94.3%) | 361 (92.8%) | 0.253 |
| Statin | 372 (96.1%) | 368 (95.3%) | 373 (95.8%) | 0.856 |
| ACEI or ARB | 243 (62.7%) | 238 (61.6%) | 263 (67.6%) | 0.186 |
| Beta-blocker | 269 (69.5%) | 284 (73.5%) | 295 (75.8%) | 0.133 |
Patients were divided according to decreasing tertile levels of fT3/fT4 ratio (Tertile1: fT3/fT4≥2.64, Tertile2: 2.28≤ fT3/fT4 <2.64, Tertile3: fT3/fT4 <2.28). BMI, body mass index; STEMI, ST-segment elevation myocardial infarction; LVEF, left ventricular ejection fraction; TIMI, Thrombolysis in Myocardial Infarction; fT3, free triiodothyronine; fT4, free thyroxine; TSH, thyroid-stimulating hormone; FBG, fasting blood glucose; LDL-C, low-density lipoprotein cholesterol; hs-CRP, high-sensitive C-reactive protein; NT-proBNP, N-terminal pro-B-type natriuretic peptide; TnI, Troponin I; DAPT, dual anti-platelet therapy; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor antagonist.